keyword
MENU ▼
Read by QxMD icon Read
search

Bioresorbable stent

keyword
https://www.readbyqxmd.com/read/28343607/bioresorbable-vascular-scaffold-during-st-elevation-myocardial-infarction-a-systematic-review
#1
REVIEW
Fabien Picard, Quentin de Hemptinne, Robert Avram, Hung Q Ly, Philippe L L'Allier, Jean-François Tanguay
BACKGROUND: The bioresorbable vascular scaffold (BVS) represents a novel technology designed to overcome the long-term limitations of metallic coronary stent implantation in percutaneous coronary intervention. In this context, primary percutaneous coronary intervention in ST-elevation myocardial infarction (STEMI) could be a preferred scenario for BVS implantation. Nevertheless, data on efficacy and safety are lacking in this specific subset of patients. METHODS: We conducted a systematic review to examine the safety and efficacy of BVS use in STEMI patients...
April 2017: Canadian Journal of Cardiology
https://www.readbyqxmd.com/read/28335892/hybrid-percutaneous-coronary-intervention-with-bioresorbable-vascular-scaffolds-in-combination-with-drug-eluting-stents-or-drug-coated-balloons-for-complex-coronary-lesions
#2
REVIEW
Akihito Tanaka, Richard J Jabbour, Satoru Mitomo, Azeem Latib, Antonio Colombo
Bioresorbable vascular scaffolds (BVS) have become an attractive option in the percutaneous coronary intervention field due to the potential advantages associated with the complete resorption process that occurs within a few years. However, current-generation BVS have several limitations including thicker struts, reduced radial strength, and limited expansion capability when compared with drug-eluting stents (DES). As a result, complex coronary disease often contains BVS-inappropriate/unfavorable segments...
March 27, 2017: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/28320687/12-months-outcomes-after-bioresorbable-vascular-scaffold-implantation-in-patients-with-acute-coronary-syndromes-data-from-the-european-multicentre-ghost-eu-extended-registry
#3
Boris Schnorbus, Jens Wiebe, Davide Capodanno, Salvatore Brugaletta, Salvatore Geraci, Julinda Mehilli, Azeem Latib, Maciej Lesiak, Christoph Jensen, Alessio Mattesini, Thomas Münzel, Piera Capranzano, Carlo Di Mario, Christoph Naber, Aleksander Araszkiewicz, Antonio Colombo, Giuseppe Caramanno, Manel Sabate, Corrado Tamburino, Holger Nef, Tommaso Gori
AIMS: We report on the mid-term outcomes of patients undergoing percutaneous coronary intervention with bioresorbable vascular scaffolds (BVS) for the treatment of acute coronary syndromes (ACS) and compare with those of patients with stable coronary artery disease (sCAD). METHODS AND RESULTS: 1477 patients underwent implantation of one or more BVS (Absorb BVS; Abbott Vascular, Santa Clara, CA, USA) at 11 European centers and were included in the GHOST-EU registry...
March 21, 2017: EuroIntervention
https://www.readbyqxmd.com/read/28315492/long-term-in-vivo-corrosion-behavior-biocompatibility-and-bioresorption-mechanism-of-a-bioresorbable-nitrided-iron-scaffold
#4
Wenjiao Lin, Li Qin, Haiping Qi, Deyuan Zhang, Gui Zhang, Runlin Gao, Hong Qiu, Ying Xia, Ping Cao, Xiang Wang, Wei Zheng
Pure iron as a potential bioresorbable material for bioresorbable coronary scaffold has major disadvantages of slow corrosion and bioresorption. However, so far, there are neither quantitative data of long-term in vivo corrosion nor direct experimental evidence for bioresorption of pure iron and its alloys, which are fundamental and vital for developing novel Fe-based alloys overcoming the intrinsic drawbacks of pure iron. This work systemically investigated scaffold performance, long-term in vivo corrosion behavior and biocompatibility of a nitrided iron coronary scaffold and explored its bioresorption mechanism...
March 14, 2017: Acta Biomaterialia
https://www.readbyqxmd.com/read/28314675/a-hybrid-strategy-with-bioresorbable-vascular-scaffolds-and-drug-eluting-stents-for-treating-complex-coronary-lesions
#5
Richard J Jabbour, Alfonso Ielasi, Akihito Tanaka, Massimo Leoncini, Bernado Cortese, Giulietta Grigis, Satoru Mitomo, Damiano Regazzoli, Gaetano Di Palma, Claudio Rapetto, Maurizio Tespili, Antonio Colombo, Azeem Latib
BACKGROUND: Due to the inherent limitations of current generation BVSs, complex coronary artery disease often contains BVS unsuitable segments. Our aim was to assess the feasibility of a hybrid approach using bioresorbable vascular scaffolds (BVSs) and drug-eluting stents (DESs) for the treatment of complex coronary artery lesions not suitable for a scaffolding only approach. METHODS: A retrospective multicenter cohort analysis was performed on patients with complex de novo or in-stent restenosis lesions treated with a hybrid BVS (Absorb BVS, Abbott Vascular, Santa Clara, CA) and DES strategy...
March 8, 2017: Cardiovascular Revascularization Medicine: Including Molecular Interventions
https://www.readbyqxmd.com/read/28299676/bioresorbable-scaffolds-for-coronary-stenosis-when-and-how-based-upon-current-studies
#6
REVIEW
Alexandre Abizaid, J Ribamar Costa
PURPOSE OF REVIEW: First-generation bioresorbable scaffolds (BRS), largely represented by the poly-l-lactic acid (PLLA) ABSORB (Abbott Vascular, Temecula, Illinois, US), have demonstrated, in low to moderate lesion complexity, similar efficacy to current generation metallic drug-eluting stents. However, a trend toward more device thrombosis has been observed, especially when the scaffolds are used in off-label situations. In this review, we address the most relevant drawbacks of these devices and, based on the available scientific data, we visit the scenarios where there is more uncertainty about their indication, trying to identify the lesions/patients to whom this technology should be voided at its current stage of development...
March 2017: Current Cardiology Reports
https://www.readbyqxmd.com/read/28295999/fracture-with-the-newer-bioresorbable-vascular-scaffolds
#7
Mostafa Elwany, Gaetano Di Palma, Bernardo Cortese
Bioresorbable vascular scaffolds (BVS) are being increasingly used in complex, real-world lesions. The possibility of strut fractures is a rare entity with the use of drug eluting stents (DES), but has not yet been adequately described for the BVS technology. In this report, we present a case of scaffold fracture of DEsolve BVS (Elixir Medical Corporation, USA) that was diagnosed both angiographically and by optical coherence tomography(OCT). Scaffold fracture with the newer BVS is a new Achilles' heel in the BVS technology...
March 15, 2017: Catheterization and Cardiovascular Interventions
https://www.readbyqxmd.com/read/28279311/antiplatelet-therapy-after-implantation-of%C3%A2-bioresorbable-vascular-scaffolds-a-review-of-the-published-data-practical-recommendations-and%C3%A2-future-directions
#8
REVIEW
Davide Capodanno, Dominick J Angiolillo
The introduction of bioresorbable vascular scaffolds (BVS) for clinical use has raised a number of questions on whether current dual-antiplatelet therapy (DAPT) recommendations after drug-eluting stent (DES) implantation, mostly deriving from data on second-generation DES, are also applicable to this completely different technology. This article aims to review the technical shortcomings of BVS-the most extensively studied fully bioresorbable coronary stent-and its contemporary rates of scaffold thrombosis, with a focus on recommendations for DAPT duration...
March 13, 2017: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/28275942/bioresorbable-polymers-and-stent-devices
#9
REVIEW
Payam Dehghani
Percutaneous coronary interventions will never become obsolete, as evolution is inherent to interventional cardiology. Current drug-eluting platforms have appreciably improved their safety and efficacy profiles in different clinical settings compared to first-generation devices such that it is difficult to consider other alternatives. However, there is definite biological plausibility to consider devices with bioabsorbable polymers and/or scaffolds. It is also an undeniable fact that many patients, based on variety of belief systems, would prefer not to have a permanently implanted device...
February 2017: Current Treatment Options in Cardiovascular Medicine
https://www.readbyqxmd.com/read/28262625/is-quantitative-coronary-angiography-reliable-in-assessing-the-late-lumen-loss-of-the-everolimus-eluting-bioresorbable-polylactide-scaffold-in-comparison-with-the-cobalt-chromium-metallic-stent
#10
Yohei Sotomi, Yoshinobu Onuma, Yosuke Miyazaki, Taku Asano, Yuki Katagiri, Erhan Tenekecioglu, Hans Jonker, Jouke Dijkstra, Robbert J de Winter, Joanna J Wykrzykowska, Gregg W Stone, Jeffrey J Popma, Ken Kozuma, Kengo Tanabe, Patrick W Serruys, Takeshi Kimura
AIMS: Immediately after stent/scaffold implantation, quantitative coronary angiography (QCA) with respect to optical coherence tomography (OCT) more severely underestimates the lumen diameter (LD) in Absorb than in XIENCE. This OCT-QCA discrepancy has not been evaluated at long-term follow-up. The present study aimed to assess the accuracy of QCA with reference to OCT in Absorb as compared to XIENCE. METHODS AND RESULTS: We assessed 2-year QCA and OCT in the ABSORB Japan randomized trial (Absorb n=87, XIENCE n=44)...
March 7, 2017: EuroIntervention
https://www.readbyqxmd.com/read/28262623/second-generation-magnesium-scaffold-magmaris-device-design-and-preclinical-evaluation-in-a-porcine-coronary-artery-model
#11
Ron Waksman, Philine Zumstein, Martin Pritsch, Eric Wittchow, Michael Haude, Capucine Lapointe-Corriveau, Guy Leclerc, Michael Joner
AIMS: The second-generation drug-eluting absorbable magnesium scaffold Magmaris, recently introduced for treatment of obstructive coronary atherosclerotic lesions, suggests a good safety profile, but preclinical assessment is important for predicting clinical performance. METHODS AND RESULTS: Ninety Magmaris scaffolds were implanted into non-diseased porcine and rabbit models. A bioresorbable vascular scaffold (Absorb) and the permanent drugeluting stent (Xience Xpedition) served as controls...
March 7, 2017: EuroIntervention
https://www.readbyqxmd.com/read/28258843/mid-to-long-term-outcome-of-patients-treated-with-everolimus-eluting-bioresorbable-vascular-scaffolds-data-of-the-bvs-registry-g%C3%A3-ttingen-predominantly-from-acs-patients
#12
Kristian Hellenkamp, Alexander Becker, Yannick D Gabriel, Gerd Hasenfuß, Mark Hünlich, Claudius Jacobshagen, Wolfgang Schillinger, Marco R Schroeter
BACKGROUND: Bioresorbable vascular scaffolds (BVS) are widely used in routine clinical practice. While previous studies reported acceptable short- to midterm outcome after BVS implantation, data on longer-term outcome are rare. METHODS: Patients treated with at least one Absorb®-BVS were consecutively enrolled. Follow-up data were assessed after 834.0 [769.0-1026.0] days. The primary device-oriented composite endpoint (DOCE) was defined as cardiovascular death, myocardial infarction (MI) and/or target lesion revascularization (TLR)...
May 1, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/28257775/emerging-and-future-therapeutic-options-for-femoropopliteal-and-infrapopliteal-endovascular-intervention
#13
REVIEW
Damianos G Kokkinidis, Ehrin J Armstrong
Despite recent advances in endovascular therapy for peripheral artery disease, current technologies remain limited by rates of long-term restenosis and application to complex lesion subsets. This article presents data on upcoming therapies, including novel drug-coated balloons, drug-eluting stents, bioresorbable scaffolds, novel drug delivery therapies to target arteries, techniques to limit postangioplasty dissection, and treatment of severely calcified lesions.
April 2017: Interventional cardiology clinics
https://www.readbyqxmd.com/read/28254259/follow-up-of-coronary-artery-patency-after-implantation-of-bioresorbable-coronary-scaffolds-the-emerging-role-of-magnetic-coronary-artery-imaging
#14
REVIEW
Marco Zuin, Gianluca Rigatelli, Fiorenzo Scaranello, Massimo Rinuncini, Claudio Picariello, Katia D'Elia, Majlinda Fejzo, Loris Roncon
Bioresorbable vascular scaffolds (BVSs) represent the newest tool in the treatment of coronary artery disease (CAD). Conversely to the previous metal stents and thanks to the polylactate-based backbone, BVSs could be visualized by magnetic resonance imaging (MRI) without artifacts. These properties allow a potential non-invasive assessment of coronary artery patency after percutaneous coronary intervention (PCI), avoiding cardiac catheterization included iodine contrast and radiation exposure, and potentially more sophisticated imaging tool as the optical coherence tomography (OCT)...
February 7, 2017: Cardiovascular Revascularization Medicine: Including Molecular Interventions
https://www.readbyqxmd.com/read/28216214/everolimus-versus-novolimus-eluting-bioresorbable-scaffolds-for-the-treatment%C3%A2-of-coronary-artery-disease-a-matched-comparison
#15
Jens Wiebe, Oliver Dörr, Hanna Ilstad, Oliver Husser, Christoph Liebetrau, Niklas Boeder, Timm Bauer, Helge Möllmann, Adnan Kastrati, Christian W Hamm, Holger M Nef
OBJECTIVES: The purpose of this study was to compare the 1-year outcome of everolimus-eluting bioresorbable scaffolds (eBRS) and Novolimus-eluting bioresorbable scaffolds (nBRS) in patients undergoing percutaneous coronary intervention in a real-life clinical practice scenario. BACKGROUND: eBRS and nBRS are available and have been proved safe for coronary artery stenting in well-selected patients. METHODS: Consecutive patients who underwent bioresorbable scaffold implantation were evaluated retrospectively via 2:1 propensity matching...
February 9, 2017: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/28158421/fate-of-post-procedural-malapposition-of-everolimus-eluting-polymeric-bioresorbable-scaffold-and-everolimus-eluting-cobalt-chromium-metallic-stent-in-human-coronary-arteries-sequential-assessment-with-optical-coherence-tomography-in-absorb-japan-trial
#16
Yohei Sotomi, Yoshinobu Onuma, Jouke Dijkstra, Yosuke Miyazaki, Ken Kozuma, Kengo Tanabe, Jeffrey J Popma, Robbert J de Winter, Patrick W Serruys, Takeshi Kimura
No abstract text is available yet for this article.
January 30, 2017: European Heart Journal Cardiovascular Imaging
https://www.readbyqxmd.com/read/28145045/intraluminal-bioresorbable-vascular-scaffold-dismantling-with-aneurysm-formation-leading-to-very-late-thrombosis
#17
Amisha Patel, Tamim Nazif, Gregg W Stone, Ziad A Ali
Coronary artery aneurysm formation has been described in patients after the placement of first-generation drug-eluting stents (DES), but is less common with newer generation metallic stents. In contrast, coronary artery aneurysm formation may be more common with the use of bioresorbable vascular scaffolds (BVS) due to the frequent formation of evaginations in the arterial wall seen with BVS. In this article, we describe a unique case of BVS dismantling and thrombus formation leading to an acute coronary syndrome thirty-two months after initial BVS placement...
February 1, 2017: Catheterization and Cardiovascular Interventions
https://www.readbyqxmd.com/read/28134094/outcome-after-long-segment-stenting-with-everolimus-eluting-bioresorbable-scaffolds-focusing-on-the-concept-of-overlapping-implantation
#18
Jens Wiebe, Oliver Dörr, Christoph Liebetrau, Timm Bauer, Eva Wilkens, Hanna Ilstad, Niklas Boeder, Albrecht Elsässer, Helge Möllmann, Christian W Hamm, Holger M Nef
INTRODUCTION AND OBJECTIVES: The implantation of bioresorbable scaffolds (BRS) is an emerging technique used in percutaneous coronary interventions. Their application has been extended to more complex lesions, although evidence is only available for simple lesions. The present study evaluated scaffold implantation in long lesions, focusing on overlapping scaffolds. METHODS: We retrospectively analyzed all consecutive patients eligible for stenting with everolimus-eluting poly-L-lactic acid-based BRS with a minimum total scaffold length of 28mm, irrespective of the number of BRS used...
December 2016: Revista Española de Cardiología
https://www.readbyqxmd.com/read/28116914/treatment-of-coronary-artery-in-stent-restenosis
#19
REVIEW
Damianos G Kokkinidis, Stephen W Waldo, Ehrin J Armstrong
Although drug-eluting stents (DES) have significantly reduced the incidence and prevalence of coronary in-stent restenosis (ISR), ISR still occurs in approximately 10% of patients in real-world practice. Areas covered: The development of newer generations of DES, drug-coated balloons (DCB) and increased use of intracoronary imaging have improved our treatment options for and pathophysiologic understanding of ISR. These technological advancements have also largely supplanted older modalities for treatment of ISR, such as brachytherapy, bare metal stents, conventional and cutting balloon angioplasty, and atherectomy devices...
March 2017: Expert Review of Cardiovascular Therapy
https://www.readbyqxmd.com/read/28115812/ivus-guided-implantation-of-bioresorbable-vascular-scaffolds-for-very-late-paclitaxel-stent-thrombosis
#20
Zhe-Zhong Lin, Wei-Ting Chang, Chun-Yen Chiang, Zhih-Cherng Chen, Po-Ming Ku
Bioresorbable vascular scaffold (BVS) implantation has been shown to be safe in patients with stable coronary disease, and effective against the thrombotic lesion and the in-stent restenosis (ISR) of the drug-eluting stent (DES). BVSs have the advantages of a snow racket concept, positive vessel remodeling, and better conformability compared with DES in acute coronary syndrome (ACS). We report on a young patient with ST-elevation myocardial infarction (STEMI) who presented to our emergency department arising from very late stent thrombosis (VLST) of a 2...
January 2017: Acta Cardiologica Sinica
keyword
keyword
116611
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"